- Home
- VCIG vs NXTS Comparison
VCIG vs NXTS Comparison
Compare VCIG & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCIG | NXTS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | Malaysia | Israel |
| Employees | N/A | 9 |
| Industry | Diversified Commercial Services | Agricultural Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 656.7K | 699.8K |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VCIG | NXTS |
|---|---|---|
| Price | $5.80 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 176.4K |
| Earning Date | 10-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.50 |
| 52 Week High | $23.40 | $53.90 |
Technical Indicators
Market Signals| Indicator | VCIG | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 30.01 |
| Support Level | $0.57 | $0.50 |
| Resistance Level | $11.58 | $0.79 |
| Average True Range (ATR) | 0.88 | 0.08 |
| MACD | 0.69 | 0.03 |
| Stochastic Oscillator | 63.63 | 23.31 |
Price Performance
Historical ComparisonAbout VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.